Lorglumide sodium

(Synonyms: CR-1409 sodium)
Customer Review

Based on 1 Customer Validation

Lorglumide sodium (CR-1409 sodium) is an orally active Cholecystokinin Receptor antagonist. Lorglumide sodium inhibits pancreatic cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and downregulates MMP-2. Lorglumide sodium inhibits gastrin-stimulated Ornithine decarboxylase activity and DNA synthesis, and shows low CCKA/CCKB selectivity. Lorglumide sodium blocks Caerulein (HY-A0190)-induced exocrine pancreatic secretion and pancreatic tissue hyperplastic changes in rats, and inhibits gallbladder emptying induced by exogenous and endogenous CCK in mice. Lorglumide sodium can be used in research related to pancreatic cancer and pancreatic exocrine function.

For research use only. We do not sell to patients.

  • Purity : 99.19%
  • CAS No.: 1021868-76-7
  • Formula: C22H31Cl2N2NaO4
  • Molecular Weight:481.39
  • Storage:

    -20°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs

All Cholecystokinin Receptor Isoforms

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00